PHASE I-II TRIAL OF ADOPTIVE IMMUNOTHERAPY WITH HAPLOIDENTICAL KIR LIGAND-MISMATCHED NATURAL KILLER CELLS IN HIGH RISK ACUTE MYELOBLASTIC LEUKEMIA PATIENTS

被引：0
|
作者：
Curti, A. [1 ,2 ]
Ruggeri, L. [3 ]
D'Addio, A. [1 ,2 ]
Urbani, E. [3 ]
Bontadini, A. [4 ,5 ]
Fruet, F. [4 ,5 ]
Giudice, V [4 ,5 ]
Dan, E. [1 ,2 ]
Motta, M. R. [1 ,2 ]
Rizzi, S. [1 ,2 ]
Paolini, S. [1 ,2 ]
Martinelli, G. [1 ,2 ]
Velardi, A. [3 ]
Baccarani, M. [1 ,2 ]
Lemoli, R. M. [1 ,2 ]
机构：
[1] Univ Bologna, Dept Hematol & Oncol L&A Seragnoli, Inst Hematol & Med Oncol L&A Seragnoli, Bologna, Italy
[2] St Orsola Marcello Malpighi Hosp, Stem Cell Res Ctr, Bologna, Italy
[3] Univ Perugia, IRCCS Fdn Transplantat Biotechnol, Div Hematol & Clin Immunol, Dept Clin Med, Perugia, Italy
[4] St Orsola Marcello Malpighi Hosp, Immunohematol Serv, Bologna, Italy
[5] St Orsola Marcello Malpighi Hosp, Blood Bank, Bologna, Italy
来源：
HAEMATOLOGICA | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P225
引用
收藏
页码：S127 / S127
页数：1
相关论文
共 50 条
  • [31] A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer
    Eleni G. Iliopoulou
    Panteleimon Kountourakis
    Michalis V. Karamouzis
    Dimitrios Doufexis
    Alexandros Ardavanis
    Constantin N. Baxevanis
    Gerasimos Rigatos
    Michael Papamichail
    Sonia A. Perez
    Cancer Immunology, Immunotherapy, 2010, 59 : 1781 - 1789
  • [32] Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study
    Modak, Shakeel
    Le Luduec, Jean-Benoit
    Cheung, Irene Y.
    Goldman, Debra A.
    Ostrovnaya, Irina
    Doubrovina, Ekaterina
    Basu, Ellen
    Kushner, Brian H.
    Kramer, Kim
    Roberts, Stephen S.
    O'Reilly, Richard J.
    Cheung, Nai-Kong V.
    Hsu, Katharine C.
    ONCOIMMUNOLOGY, 2018, 7 (08):
  • [33] Ruxolitinib or Dasatinib in Combination with Chemotherapy for Patients with Relapsed/Refractory Philadelphia (Ph)-like Acute Lymphoblastic Leukemia: A Phase I-II Trial
    Jain, Nitin
    Jabbour, Elias J.
    McKay, Patrick Zweider
    Ravandi, Farhad
    Takahashi, Koichi
    Kadia, Tapan
    Wierda, William G.
    Rytting, Michael E.
    Nunez, Cesar
    Patel, Keyur
    Lu, Xinyan
    Tang, Guilin
    Konoplev, Sergej Naumovich
    Wang, Sa A.
    Han, Lina
    Thakral, Beenu
    Roberts, Kathryn G.
    Deshmukh, April
    Garris, Rebecca
    Jorgensen, Jeffrey L.
    Cavazos, Antonio
    Verstovsek, Srdan
    Garcia-Manero, Guillermo
    O'Brien, Susan M.
    Cortes, Jorge E.
    Mullighan, Charles G.
    Kantarjianand, Hagop M.
    Konopleva, Marina
    BLOOD, 2017, 130
  • [34] Safety and Efficacy of SARS-COV-2-Specific T Cells as Adoptive Immunotherapy for High-Risk COVID-19 Patients: A Phase I/II, Randomized Clinical Trial
    Papadopoulou, Anastasia
    Karavalakis, George
    Papadopoulou, Efthymia
    Xochelli, Aliki
    Bousiou, Zoi
    Vogiatzoglou, Anastasios
    Papayanni, Penelope
    Georgakopoulou, Aphrodite
    Giannaki, Maria
    Stavridou, Fani
    Vallianou, Ioanna
    Kammenou, Maria
    Varsamoudi, Evangelia
    Papadimitriou, Vasiliki
    Giannaki, Chrysavgi
    Sileli, Maria
    Stergiouda, Zoi
    Stefanou, Garyfallia
    Kourlaba, Georgia
    Triantafyllidou, Maria
    Siotou, Eleni
    Karaglani, Antonia
    Zotou, Eleni
    Chatzika, Georgia
    Boukla, Anna
    Apostolou, Dimitra
    Pitsiou, Georgia
    Morfesis, Petros
    Bartzoudis, Dimitris
    Imprialos, Konstantinos
    Karampatakis, Theodoros
    Kapravelos, Nikolaos
    Bitzani, Militsa
    Theodorakopoulou, Maria
    Serasli, Eva
    Sakellari, Ioanna
    Fylaktou, Asimina
    Tryfon, Stavros
    Anagnostopoulos, Achilles
    Yannaki, Evangelia
    MOLECULAR THERAPY, 2022, 30 (04) : 551 - 551
  • [35] SAFETY AND EFFICACY OF SARS-COV-2-SPECIFIC T CELLS AS ADOPTIVE IMMUNOTHERAPY FOR HIGH-RISK COVID-19 PATIENTS: A PHASE I/II, RANDOMIZED CLINICAL TRIAL
    Papadopoulou, A.
    Karavalakis, G.
    Papadopoulou, E.
    Xochelli, A.
    Bousiou, Z.
    Vogiatzoglou, A.
    Papayanni, P. G.
    Georgakopoulou, A.
    Giannaki, M.
    Stavridou, F.
    Vallianou, I.
    Kammenou, M.
    Varsamoudi, E.
    Papadimitriou, V.
    Giannaki, C.
    Sileli, M.
    Stergiouda, Z.
    Stefanou, G.
    Kourlaba, G.
    Triantafyllidou, M.
    Siotou, E.
    Karaglani, A.
    Zotou, E.
    Chatzika, G.
    Boukla, A.
    Apostolou, D.
    Pitsiou, G.
    Morfesis, P.
    Bartzoudis, D.
    Imprialos, K.
    Karampatakis, T.
    Kapravelos, N.
    Bitzani, M.
    Theodorakopoulou, M.
    Serasli, E.
    Sakellari, I.
    Fylaktou, A.
    Tryfon, S.
    Anagnostopoulos, A.
    Yannaki, E.
    CYTOTHERAPY, 2022, 24 (05) : S37 - S38
  • [36] A phase I-II study of intensified induction and consolidation therapy with gemtuzumab-ozogamycin for patients with high-risk acute myeloid leukemia: The AIM protocol
    Sivasubramaniam, VH
    Hiemenz, J
    Ballester, OF
    BLOOD, 2002, 100 (11) : 269B - 269B
  • [37] A Phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia
    Koller, CA
    Kantarjian, HM
    Feldman, EJ
    O'Brien, S
    Rios, MB
    Estey, E
    Keating, M
    CANCER, 1999, 86 (11) : 2246 - 2251
  • [38] Preventing GvHD and high-risk acute leukemia relapse by Treg and Tcon adoptive immunotherapy in HLA-haploidentical transplantation: an update on the clinical trial and insights from murine studies
    Ruggeri, L.
    Di Ianni, M.
    Falzetti, F.
    Carotti, A.
    Terenzi, A.
    Massei, M. S.
    Amico, L.
    Pierini, A.
    Urbani, E.
    Falini, B.
    Martelli, M. F.
    Velardi, A.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S21 - S21
  • [39] Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer
    Ishikawa, Takeshi
    Okayama, Tetsuya
    Sakamoto, Naoyuki
    Ideno, Mitsuko
    Oka, Kaname
    Enoki, Tatsuji
    Mineno, Junichi
    Yoshida, Naohisa
    Katada, Kazuhiro
    Kamada, Kazuhiro
    Uchiyama, Kazuhiko
    Handa, Osamu
    Takagi, Tomohisa
    Konishi, Hideyuki
    Kokura, Satoshi
    Uno, Kazuko
    Naito, Yuji
    Itoh, Yoshito
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (12) : 2599 - 2609
  • [40] Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality
    Issa, Ghayas C.
    Kantarjian, Hagop M.
    Xiao, Lianchun
    Ning, Jing
    Alvarado, Yesid
    Borthakur, Gautam
    Daver, Naval
    DiNardo, Courtney D.
    Jabbour, Elias
    Bose, Prithviraj
    Jain, Nitin
    Kadia, Tapan M.
    Naqvi, Kiran
    Pemmaraju, Naveen
    Takahashi, Koichi
    Verstovsek, Srdan
    Andreeff, Micheal
    Kornblau, Steven M.
    Estrov, Zeev
    Ferrajoli, Alessandra
    Garcia-Manero, Guillermo
    Ohanian, Maro
    Wierda, William G.
    Ravandi, Farhad
    Cortes, Jorge E.
    LEUKEMIA, 2020, 34 (11) : 2914 - 2924
12345